Diagnosing COPD involves having a post-bronchodilator FEV1/FVC ratio of less than 0.65, while the Global Initiative for Chronic Obstructive Lung Disease recommends incorporating both short-acting beta2-agonists and anticholinergics in the bronchodilator response evaluation.